$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Ivonib (ivitinib)/azacitidine combination shows clinical benefit in IDH1 mutant AML
2026-02-01 22:25:32
Check Details
Early application study of ivonib (ivitinib) in patients with acute pancreatitis
2026-02-01 22:25:32
Check Details
Ivonib (Ivitinib) Significantly Reduces Triazole Levels in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
2026-02-01 22:25:32
Check Details
Clinical application of ivonib (ivitinib) in the treatment of insulin-resistant type 1 diabetes
2026-02-01 22:25:32
Check Details
What is the manufacturer of avatrombopag (Sucoxin)?
2026-02-01 22:25:32
Check Details
Avatrombopag (Sucoxin) Instructions
2026-02-01 22:25:32
Check Details
Avatrombopag (Sucoxin) usage and dosage
2026-02-01 22:25:32
Check Details
How many days does avatrombopag (Su Kexin) take to increase platelets and take effect?
2026-02-01 22:25:32
Check Details
Avatrombopag (Su Kexin) is not reimbursed by medical insurance
2026-02-01 22:25:32
Check Details
What does dasatinib treat?
2026-02-01 22:25:32
Check Details
What are the common side effects of dasatinib?
2026-02-01 22:25:32
Check Details
What should I pay attention to while taking dasatinib?
2026-02-01 22:25:32
Check Details
1
2
...
735
736
737
738
739
740
741
...
10222
10223
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Elagolix Side Effects and Safety Guide
2
Hetrombopag vs. Avatrombopag: Key Differences Between Two Oral TPO-RAs and Safety Considerations
3
Lytenava: The First FDA-Approved Ophthalmic Bevacizumab Formulation
4
FDA Approves Lytenava: First Ophthalmic Bevacizumab for Wet AMD
5
Simtriyo (Centanafadine): World's First NDSRI ADHD Drug Approved by FDA
6
Lipfendra (Enlicitide): The World's First Oral PCSK9 Inhibitor Approved by FDA
7
Orforglipron: The World's First Oral Small-Molecule GLP-1 Receptor Agonist for Weight Management
8
Cabozantinib Capsules: A Multi-Targeted Therapy for Progressive Medullary Thyroid Cancer
9
Lorlatinib: Mechanism, Advantages, and Key Considerations of Third-Generation ALK Inhibitor Therapy in ALK-Positive NSCLC
10
FDA Approves Subcutaneous Isatuximab (Sarclisa) for Multiple Myeloma: A New Administration Option
11
Pemigatinib Side Effects Explained: Managing Adverse Reactions of FGFR-Targeted Therapy in Cholangiocarcinoma
12
Selpercatinib: Before or After Meals? A Complete Guide to RET-Targeted Therapy Administration